Fatebenefratelli Hospital, Rome, Italy.
Am Heart J. 2011 Aug;162(2):390-7. doi: 10.1016/j.ahj.2011.04.008. Epub 2011 Jul 7.
Clinical practice with regard to defibrillation threshold (DFT) testing during implantable cardioverter-defibrillator (ICD) implantation varies considerably, even among experienced implanting centers. International guidelines do not as yet mandate DFT testing.
The objective of this project is to assess current clinical decision making regarding DFT testing during ICD implantation.
The ALIVE project collected data on DFT testing from a multicenter network of Italian clinicians sharing a common system for the collection, management, analysis, and reporting of clinical and diagnostic data from patients with Medtronic (Minneapolis, MN) implantable devices.
Data on 2,082 consecutive patients implanted with a Medtronic ICD in 111 Italian centers, over the period 2007 to 2010, were analyzed. Defibrillation threshold testing was performed in 33% of cases (678/2,082). The main reasons for performing the test were physician's clinical practice ("I always perform DFT") (80%) and secondary prevention implantation (12%). The main reasons for not performing DFT testing were centers' practice (44%), primary prevention (31%), and device replacement (15%). In 22 patients, ventricular fibrillation induction was not achieved; 656 patients completed DFT testing: 633 patients (96%) performed a single test, 19 patients (3%) performed a second induction test, and 4 patients (0.6%) underwent an additional induction test.
The preliminary results of the ALIVE project show that a great number of implant procedures are performed without DFT testing in the common practice of the participating centers. We also measured an inhomogeneous, center-dependent DFT testing behavior, which suggests the importance of defining a common guideline for ICD implant testing. Follow-up data on our patients will provide more information on the clinical value of the test.
即使在经验丰富的植入中心,心脏再同步复律除颤器(ICD)植入过程中关于除颤阈值(DFT)测试的临床实践也存在很大差异。国际指南尚未规定进行 DFT 测试。
本项目旨在评估目前在 ICD 植入过程中进行 DFT 测试的临床决策。
ALIVE 项目从意大利多中心临床医生网络中收集了关于 DFT 测试的数据,该网络共享一个用于收集、管理、分析和报告美敦力(明尼苏达州明尼阿波利斯)植入设备患者的临床和诊断数据的通用系统。
分析了 2007 年至 2010 年间在 111 个意大利中心植入 2082 例连续患者的 DFT 测试数据。在 678/2082 例病例中进行了除颤阈值测试。进行测试的主要原因是医生的临床实践(“我总是进行 DFT”)(80%)和二级预防植入(12%)。不进行 DFT 测试的主要原因是中心的实践(44%)、一级预防(31%)和设备更换(15%)。在 22 名患者中,未能诱发心室颤动;656 名患者完成了 DFT 测试:633 名患者(96%)进行了单次测试,19 名患者(3%)进行了第二次诱导测试,4 名患者(0.6%)进行了额外的诱导测试。
ALIVE 项目的初步结果表明,在参与中心的常见实践中,许多植入程序在没有 DFT 测试的情况下进行。我们还测量了一种不均匀的、依赖中心的 DFT 测试行为,这表明为 ICD 植入测试定义一个共同的指南非常重要。对我们患者的随访数据将提供更多关于测试临床价值的信息。